Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | PO / MO |
The patient was supposed to take the third capsule of Vivotif yesterday morning, but forgot; Case reference number US-BN-2025-001454 is a spontaneous case initially received from a consumer via Communications (reference number: USBAV25-2116) on 25-Aug-2025 and concerns a patient of unspecified age and gender. The patient's medical history and concomitant medication details were not provided. On unspecified dates (every other day), the patient took the first two Vivotif capsules (batch number: unknown) at an unknown dose, orally, for unknown indication. As reported on 24-Aug-2025, the patient was supposed to take the third Vivotif capsule, but they forgot (explicitly coded as 'missed dose'). At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif. No additional information was provided.; Reporter's Comments: This case concerns a patient of unspecified age and gender. As reported patient took the first two Vivotif capsules for an unknown indication, and was supposed to take the third Vivotif capsule, but forgot, which is considered as product dose omission issue. Product dose omission issue is considered as listed per company convention. At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns a patient of unspecified age and gender. As reported patient took the first two Vivotif capsules for an unknown indication, and was supposed to take the third Vivotif capsule, but forgot, which is considered as product dose omission issue. Product dose omission issue is considered as listed per company convention. At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None